What are the top most costly diseases for USA? The alignment of burden of illness with prevention and screening expenditures (original) (raw)
Related papers
Costs of illness: United States, 1980
National Medical Care Utilization and Expenditure Survey (Series). Series C, Analytical report, 1986
The total costs of illness and injury in the U.S. civilian noninstitutionalized population in 1980 amounted to 381.7billion.Thedirectcostsofillnessandinjury−−resourceexpendituresforthediagnosis,treatment,andmanagementofmedicalanddentalconditions−−were381.7 billion. The direct costs of illness and injury--resource expenditures for the diagnosis, treatment, and management of medical and dental conditions--were 381.7billion.Thedirectcostsofillnessandinjury−−resourceexpendituresforthediagnosis,treatment,andmanagementofmedicalanddentalconditions−−were153.9 billion, or 40.3 percent of total costs. Indirect costs--economic losses from morbidity and mortality--were 227.9billion,or59.7percentoftotalcosts.Ofindirectcosts,227.9 billion, or 59.7 percent of total costs. Of indirect costs, 227.9billion,or59.7percentoftotalcosts.Ofindirectcosts,104.9 billion resulted from productivity losses because of morbidity, and $123.0 billion represent the present value of lost productivity from premature mortality based on a net effective discount rate of 4 percent. These estimates, based on data from the 1980. National Medical Care Utilization and Expenditure Survey (NMCUES), differ from other estimates of the costs of illness and injury in 1980 (Gibson and Waldo, 1982; Rice, Hodgson, and Kopstein, 1985). The differences, which can be resolved, are attributable to two major factors: (...
Costs of Chronic Diseases at the State Level: The Chronic Disease Cost Calculator
Preventing chronic disease, 2015
Many studies have estimated national chronic disease costs, but state-level estimates are limited. The Centers for Disease Control and Prevention developed the Chronic Disease Cost Calculator (CDCC), which estimates state-level costs for arthritis, asthma, cancer, congestive heart failure, coronary heart disease, hypertension, stroke, other heart diseases, depression, and diabetes. Using publicly available and restricted secondary data from multiple national data sets from 2004 through 2008, disease-attributable annual per-person medical and absenteeism costs were estimated. Total state medical and absenteeism costs were derived by multiplying per person costs from regressions by the number of people in the state treated for each disease. Medical costs were estimated for all payers and separately for Medicaid, Medicare, and private insurers. Projected medical costs for all payers (2010 through 2020) were calculated using medical costs and projected state population counts. Median st...
US Spending on Personal Health Care and Public Health, 1996-2013
JAMA, 2016
US health care spending has continued to increase, and now accounts for more than 17% of the US economy. Despite the size and growth of this spending, little is known about how spending on each condition varies by age and across time. To systematically and comprehensively estimate US spending on personal health care and public health, according to condition, age and sex group, and type of care. Government budgets, insurance claims, facility surveys, household surveys, and official US records from 1996 through 2013 were collected and combined. In total, 183 sources of data were used to estimate spending for 155 conditions (including cancer, which was disaggregated into 29 conditions). For each record, spending was extracted, along with the age and sex of the patient, and the type of care. Spending was adjusted to reflect the health condition treated, rather than the primary diagnosis. Encounter with US health care system. National spending estimates stratified by condition, age and s...
BMC Health Services Research, 2011
Background The allocation of limited available healthcare resources demands an agreed rational allocation principle and the consequent priority setting. We assessed the association between economic evaluations of healthcare interventions published in Spain (1983-2008) and the disease burden in the population. Methods Electronic databases (e.g., PubMed/MEDLINE, SCOPUS, ISI Web of Knowledge, CRD, IME, IBECS) and reports from health technology assessment agencies were systematically reviewed. For each article, multiple variables were recorded such as: year and journal of publication, type of study, health intervention targetted, perspective of analysis, type of costs and sources of information, first author's affiliation, explicit recommendations aimed at decision-making, and the main disease cause to which the intervention was addressed. The following disease burden measures were calculated: years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted life years (DALYs), and mortality by cause. Correlation and linear regression models were fitted. Results Four hundred and seventy-seven economic evaluations were identified. Cardiovascular diseases (15.7%), infectious diseases (15.3%), malignant neoplasms (13.2%), and neuropsychiatric diseases (9.6%) were the conditions most commonly addressed. Accidents and injuries, congenital anomalies, oral conditions, nutritional deficiencies and other neoplasms were the categories with a lowest number of studies (0.6% for each of them). For the main disease categories (n = 20), a correlation was seen with: mortality 0.67 (p = 0.001), DALYs 0.63 (p = 0.003), YLLs 0.54 (p = 0.014), and YLDs 0.51 (p = 0.018). By disease sub-categories (n = 51), the correlations were generally low and non statistically significant. Conclusions Examining discrepancies between economic evaluations in particular diseases and the overall burden of disease helps shed light on whether there are potentially over- and under-investigated areas. The approach taken could help policy-makers understand whether resources for economic evaluation are being allocated by using summary measures of population health.
The Cost of Treating Chronic Non-Communicable Diseases: Does it Matter?
2012
Heart disease and Type 2 diabetes mellitus are among the two leading causes of death in the CARICOM member states with HIV/AIDS a distant sixth. Attention is now being paid to non-communicable diseases which have outpaced communicable diseases as the major cause of death. This paper investigated the link between the public medical cost of treating chronic non-communicable diseases, namely heart disease and diabetes, on national output in Barbados, Guyana, Jamaica, and Trinidad and Tobago. The results provide evidence that the public medical cost of treating chronic non-communicable diseases does have a statistically significant negative impact on national output.